70
Participants
Start Date
May 2, 2017
Primary Completion Date
January 25, 2019
Study Completion Date
July 13, 2020
Epacadostat
Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
Pembrolizumab
Pembrolizumab
Oxaliplatin
Oxaliplatin
Leucovorin
Leucovorin
5-Fluorouracil
5-Fluorouracil
Gemcitabine
Gemcitabine
nab-Paclitaxel
nab-Paclitaxel
Carboplatin
Carboplatin
Paclitaxel
Paclitaxel
Pemetrexed
Pemetrexed
Cyclophosphamide
Cyclophosphamide
Carboplatin
Carboplatin
Cisplatin
Cisplatin
5-Fluorouracil
5-FU
Investigator's choice of platinum agent
Investigator's choice of platinum agent: carboplatin or cisplatin
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh Cancer Institute, Pittsburgh
University of Pennsylvania Health System, Philadelphia
Carolina Bio-Oncology Institute, PLLC, Huntersville
Mayo Clinic, Jacksonville
Tennessee Oncology - Nashville; The Sarah Cannon Research Institute, Nashville
Vanderbilt University; Henry Joyce Cancer Clinic, Nashville
Mayo Clinic, Rochester
University of Chicago, Chicago
Washington University School of Medicine, St Louis
MD Anderson Cancer Center, Houston
Huntsman Cancer Institute at University of Utah, Salt Lake City
Mayo Clinic Arizona, Phoenix
The Angeles Clinic and Research Institute, Los Angeles
University of California San Diego Medical Center, Moores Cancer Center, La Jolla
Oregon Health and Science University, Portland
Lead Sponsor
Incyte Corporation
INDUSTRY